Levels of the enzyme PRDX2 increase as a protective response in chronic thromboembolic pulmonary hypertension (CTEPH) and help reduce damage to blood vessels in the lungs, a new study in laboratory rats has found. The researchers discovered that the antioxidant enzyme worked to reduce vessel damage by limiting inflammation,…
A weight-based dose regimen of Uptravi (selexipag) for children with pulmonary arterial hypertension (PAH) achieves drug exposure similar to that of the standard adult dose regimen, according to results from a Phase 2 clinical trial. The study also found that the weight-based Uptravi regimen for kids is comparable…
Yutrepia, an inhaled dry powder formulation of treprostinil that won regulatory approval in the U.S. in May 2025, was prescribed to more than 2,800 patients through December of last year, according to its developer Liquidia. Overall, more than 2,200 patients have started treatment, per the biopharmaceutical company, which…
Women with pulmonary hypertension have a lower risk of death than men, a difference that persists regardless of how severe the disease is, how old patients are, or how they are treated, a large study found. The disparity mainly affected white patients, the researchers said. “These insights provide new…
People with chronic thromboembolic pulmonary hypertension (CTEPH) continue to experience significant symptoms that interfere with daily life, even when receiving treatment, according to a real-world U.S. study. The study also found that people treated at Pulmonary Hypertension Association (PHA)-accredited centers tended to have more severe…
Early diagnosis of pulmonary arterial hypertension (PAH), less than six months after symptom onset, improves five-year survival by 42% compared with delayed diagnosis of about two years or more, a recent study shows. The study also found that high blood pressure during heart contraction or normal pressure during heart relaxation,…
Routine heart ultrasound measurements of left ventricular (LV) underfilling may significantly improve the prediction of poorer outcomes in people with pulmonary arterial hypertension (PAH) beyond currently used prognostic tools, a study has found. LV underfilling refers to the extent to which the left ventricle, the heart chamber that pumps…
Pulmonary hypertension (PH) in extremely premature infants — those born before 28 weeks of pregnancy — who also have bronchopulmonary dysplasia (BPD) usually resolves within the first year and does not…
Researchers have pinpointed Jagged-2, a signaling protein, as a potential therapeutic target for slowing or halting the progression of pulmonary arterial hypertension (PAH), based on a rat study. Suppressing Jagged-2 in a rat model reversed various processes that drive PAH progression, including inflammation and oxidative stress, a form of…
Two Phase 3 clinical trials are now recruiting participants to test Tenax Therapeutics‘ experimental therapy TNX-103 (oral levosimendan) in people with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). Tenax said its ongoing Phase 3 trial, LEVEL (NCT05983250), is expected to finish enrollment next year.
Uptravi (selexipag) may reduce blood pressure in the lungs of children with pulmonary arterial hypertension (PAH) and help them perform physical tasks, according to a meta-analysis. However, more long-term studies are still needed to confirm these benefits. The study, “Efficacy and Tolerability of Selexipag in…
A committee of the European Medicines Agency (EMA) has recommended expanding the indication for Winrevair (sotatercept-csrk), Merck’s approved injection therapy for adults with pulmonary arterial hypertension (PAH). Winrevair was approved in the European Union last year. It is currently indicated for use in combination with…
Get regular updates to your inbox.
